Cargando…

Surgical therapy of primary hepatic angiosarcoma

BACKGROUND: Primary hepatic angiosarcoma (PHA) is a rare tumor entity. Radical surgical resection is currently considered the best treatment choice. The aim of this analysis is to report our experience with surgery for PHA. METHODS: All resections of PHA from 01/2002 until 06/2017 were identified fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripke, Verena, Heinrich, Stefan, Huber, Tobias, Mittler, Jens, Hoppe-Lotichius, Maria, Straub, Beate K., Lang, Hauke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329081/
https://www.ncbi.nlm.nih.gov/pubmed/30630447
http://dx.doi.org/10.1186/s12893-018-0465-5
_version_ 1783386764635799552
author Tripke, Verena
Heinrich, Stefan
Huber, Tobias
Mittler, Jens
Hoppe-Lotichius, Maria
Straub, Beate K.
Lang, Hauke
author_facet Tripke, Verena
Heinrich, Stefan
Huber, Tobias
Mittler, Jens
Hoppe-Lotichius, Maria
Straub, Beate K.
Lang, Hauke
author_sort Tripke, Verena
collection PubMed
description BACKGROUND: Primary hepatic angiosarcoma (PHA) is a rare tumor entity. Radical surgical resection is currently considered the best treatment choice. The aim of this analysis is to report our experience with surgery for PHA. METHODS: All resections of PHA from 01/2002 until 06/2017 were identified from our prospective institutional database. All cases were re-confirmed by a second pathologist. We analyzed completeness of resection, overall (OS) and disease-free survival (DFS). RESULTS: Nine patients with PHA underwent hepatic resection. Median follow-up after surgery was 15.5 months (range: 3–144). At last follow-up 4/9 patients were alive, three of them without recurrence 15, 21 and 144 months after surgery. Five patients developed PHA recurrence. Four of these died 3 to 17 months after surgery. One patient with PHA recurrence is alive 15 months after surgery. Another patient without PHA recurrence died 59 months after surgery from pancreatic cancer. Median OS and DFS after resection was 18 months (range: 3–144 months) and 10 months (range: 2–144 months), respectively. After R-0 resection (n = 8), the median OS and DFS was 59 and 11 months. CONCLUSIONS: Resection of PHA is the only approach to achieve complete tumor removal and offers a chance for long-term survival and should be evaluated in cases of PHA.
format Online
Article
Text
id pubmed-6329081
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63290812019-01-16 Surgical therapy of primary hepatic angiosarcoma Tripke, Verena Heinrich, Stefan Huber, Tobias Mittler, Jens Hoppe-Lotichius, Maria Straub, Beate K. Lang, Hauke BMC Surg Research Article BACKGROUND: Primary hepatic angiosarcoma (PHA) is a rare tumor entity. Radical surgical resection is currently considered the best treatment choice. The aim of this analysis is to report our experience with surgery for PHA. METHODS: All resections of PHA from 01/2002 until 06/2017 were identified from our prospective institutional database. All cases were re-confirmed by a second pathologist. We analyzed completeness of resection, overall (OS) and disease-free survival (DFS). RESULTS: Nine patients with PHA underwent hepatic resection. Median follow-up after surgery was 15.5 months (range: 3–144). At last follow-up 4/9 patients were alive, three of them without recurrence 15, 21 and 144 months after surgery. Five patients developed PHA recurrence. Four of these died 3 to 17 months after surgery. One patient with PHA recurrence is alive 15 months after surgery. Another patient without PHA recurrence died 59 months after surgery from pancreatic cancer. Median OS and DFS after resection was 18 months (range: 3–144 months) and 10 months (range: 2–144 months), respectively. After R-0 resection (n = 8), the median OS and DFS was 59 and 11 months. CONCLUSIONS: Resection of PHA is the only approach to achieve complete tumor removal and offers a chance for long-term survival and should be evaluated in cases of PHA. BioMed Central 2019-01-10 /pmc/articles/PMC6329081/ /pubmed/30630447 http://dx.doi.org/10.1186/s12893-018-0465-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tripke, Verena
Heinrich, Stefan
Huber, Tobias
Mittler, Jens
Hoppe-Lotichius, Maria
Straub, Beate K.
Lang, Hauke
Surgical therapy of primary hepatic angiosarcoma
title Surgical therapy of primary hepatic angiosarcoma
title_full Surgical therapy of primary hepatic angiosarcoma
title_fullStr Surgical therapy of primary hepatic angiosarcoma
title_full_unstemmed Surgical therapy of primary hepatic angiosarcoma
title_short Surgical therapy of primary hepatic angiosarcoma
title_sort surgical therapy of primary hepatic angiosarcoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329081/
https://www.ncbi.nlm.nih.gov/pubmed/30630447
http://dx.doi.org/10.1186/s12893-018-0465-5
work_keys_str_mv AT tripkeverena surgicaltherapyofprimaryhepaticangiosarcoma
AT heinrichstefan surgicaltherapyofprimaryhepaticangiosarcoma
AT hubertobias surgicaltherapyofprimaryhepaticangiosarcoma
AT mittlerjens surgicaltherapyofprimaryhepaticangiosarcoma
AT hoppelotichiusmaria surgicaltherapyofprimaryhepaticangiosarcoma
AT straubbeatek surgicaltherapyofprimaryhepaticangiosarcoma
AT langhauke surgicaltherapyofprimaryhepaticangiosarcoma